Dan Wasserman is the founder and CEO of Mammoth Health Innovation and the creator of CHIEFS (Customers, Health Economics, Impact, Execution, Financials and Scalability), a tool that benchmarks a Canadian health innovation against an American one at the same stage of development, then lays out the actions needed to level the playing field. Over a 40-year career, with the past 28 years split between Canada and the United States, Dan has worked in competitive intelligence, IP insights and business development for IBM, AT&T, Hollywood studios, airlines and banks. He also spent a decade in Washington, DC, including lobbying on Capitol Hill. He mentored early-stage companies at ventureLAB, where he created the Health Ecosphere program before spinning out Mammoth, and he is an adjunct professor in the innovation stream at the Icahn School of Medicine at Mount Sinai. Dan holds a biology degree from the University of Toronto and an MBA from the Schulich School of Business, and he is a published novelist. Dan opens with a story about commercial creativity. In the mid-1990s, Sympatico, the phone companies’ new internet service, was falling far short of its sign-up target. Dan struck a deal with Christie to put instant-win Sympatico offers inside Oreo packages across the country. The launch finished the year with 140,000 sign-ups against a goal of 100,000, and “the only thing Christie insisted we pay for was the $300 in colour separations.” From there, he compares how the two countries think about commercialization. In the US, SBIR and STTR funding expects a commercialization plan, and investors ask founders how they deployed that money and whether they have pre-sales. In Canada, he sees strong support for research and far less for getting products to market. He describes the Health Ecosphere he built at ventureLAB, which brought together finance, legal, IP, government and hospital partners after health system leaders said they welcomed innovation and the companies in the room said they couldn’t get through the door. The work later received FedDev funding, and Dan sees its legacy in CAN Health Network and OBIO’s Early Adopter Health Network. Dan then walks through how CHIEFS came to be. He started from 50 criteria that separate American successes from Canadian ones, distilled them into 10 factors, and organized them into six pillars. A factors report shows innovators where they need to pull their socks up, and a pillars profile tells investors whether a company is worth considering. Execution is where companies fall down most often, he says, and the smartest scientific founders bring in business people early, because “100% of zero is still zero.” The conversation closes on what it takes to keep companies in Canada. Dan makes the case for exits to Canadian buyers backed by Canadian pension capital, and traces part of the problem to the 1990s Bank Act changes. He explains what Canada should copy from the holding-period rules in the US QSBS program, and why US funders back several competitors at once so that failure isn’t a penalty. He also talks about Canada’s shortage of commercialization talent, what Estonia’s integrated digital systems show is possible, and why drugs designed by AI still have to prove themselves in human trials. Dan’s message is that Canada already pays for the science, and the next step is building commercialization into how we fund, buy and keep our innovations. If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it. 🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey. 🔗 Questions, feedback, or want to connect? https://augmentios.com/contact 📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter #BreakingInnovationParalysis #CanadianInnovation #Commercialization #HealthInnovation #Procurement #VentureCapital #HealthPolicy